EU Nations Demand Broader Cost Analysis of Wastewater Directive, Citing Medicine Access Concerns
Table of Contents
Fifteen European Union member states are pressing the European Commission for a more comprehensive cost study regarding the new Urban Wastewater Treatment Directive, arguing that the current focus on environmental and infrastructure impacts is insufficient. The nations, led by Czechia, are particularly concerned about the potential effects on the availability and price of essential medicines.
The push for a wider-ranging analysis builds on previous discussions initiated by Germany in June, which secured a commitment from the Commission to update the economic evaluation of the extended producer responsibility (EPR) system outlined in the directive. While welcoming this initial step, the fifteen countries believe a narrower focus on purification costs overlooks critical implications for healthcare systems and pharmaceutical supply chains.
Protecting Access to Essential Medicines
At the heart of the debate lies the potential for increased costs associated with advanced wastewater treatment to disrupt the pharmaceutical market. Czechia, speaking at the Council of Employment, Social Policy, Health and Consumers (EPSCO) on December 2, emphasized the necessity of the directive for both environmental protection and infrastructure development, but cautioned against unintended consequences. “I am concerned about the use of penicillin, above all, since the additional cost of water treatment would also reduce the profitability and protection of penicillin,” a senior official stated, extending the concern to broad-spectrum antibiotics.
The Czech delegation underscored that combating antimicrobial resistance requires appropriate antibiotic use, not measures that could lead to essential medications being removed from the market. They expressed a willingness to collaborate with the Commission, providing detailed data on costs and margins within the antibiotic segment to inform a more accurate assessment.
Concerns Extend Across the Union
Germany echoed these concerns, with a minister stressing the need for precise financial figures before fully implementing the EPR. He applauded the Commission’s efforts to update the cost study, but emphasized the importance of understanding the implications for both the health system and the availability of critical medicines. “It is essential to know the effect…for the critical components of medicines at the healthcare level,” he said, also calling for the report to be available within a “reasonable period” to facilitate supply chain planning.
Italy brought a patient-centered perspective to the discussion, advocating for the cost study to analyze the impact on national healthcare systems and ensure continued affordability and access to medicines. A representative warned that combining new fixed costs with existing inflationary pressures could lead to price increases or supply shortages, exacerbating inequalities in healthcare access. For Italy, environmental sustainability and the sustainability of national health systems are “inseparable,” aligning with a “one health” approach.
The Netherlands focused on the model’s architecture, supporting an updated cost study that is “exhaustive” and “independently verified.” They urged the Commission to clearly differentiate costs attributable to the pharmaceutical sector versus the cosmetics sector and to expedite the drafting and execution phases to avoid a fragmented regulatory landscape.
Vulnerability of Smaller Markets and Generics
A recurring theme throughout the debate was the particular vulnerability of smaller markets and generic medicines. Malta argued for a thorough analysis of the financial and access implications of the program, while Lithuania warned that the EPR system could negatively impact the availability and affordability of medicines, potentially leading to price increases, increased pressure on mandatory health insurance, and shortages – particularly of generics.
Estonia similarly expressed doubts about the directive’s impact, warning that the RAP system could raise prices for both health systems and patients, especially in countries with limited sales volumes and suppliers. Several other nations, including Cyprus, Bulgaria, and Romania, aligned with this assessment. Greece went further, demanding a clear indication that Article 9 of the directive cannot be applied in its current form until conclusive results are available, fearing it would lead to increased medicine prices and competitive disadvantages.
Portugal highlighted the importance of economic sustainability and the role of generic medicines, advocating for the RAP to consider product accessibility and existing infrastructure. Austria emphasized the need for a comprehensive cost report to ensure realistic implementation deadlines by 2026.
Commission Responds, Leaves Door Open to Adjustments
In his closing remarks, Health Commissioner Oliver Várhelyi reaffirmed the directive’s goal of improving water quality and protecting human health by eliminating micropollutants through advanced treatment financed by an RAP system applied to the pharmaceutical and cosmetic sectors. He stated that these sectors are expected to finance “at least 80 percent of the total cost of this quaternary treatment.”
The commissioner confirmed that the Commission is already conducting a study to update the estimated cost of the RAP and its potential impact on affected sectors. He also acknowledged the member states’ priority of ensuring medicine availability and robust national health system budgets, stating bluntly: “There is no patient who can be deprived of a medicine that can save their life, simply because it is not feasible to have it available on the market.”
Várhelyi also indicated a willingness to adjust the implementation timeline if the data warrants it, noting that the Commission must be prepared to “reach our own conclusions or modify our approach, such as postponing the implementation or giving a time period for the review of these measures” based on the study’s findings.
A Long-Simmering Debate
This debate at EPSCO follows two years of tension between member states and the pharmaceutical industry over the Wastewater Directive. Approved by the EU Council in 2024, the directive introduces the RAP mechanism, requiring producers to assume at least 80% of the cost of new quaternary treatment to eliminate micropollutants, with a 31-month adaptation period for national legislation.
Throughout this period, the pharmaceutical industry has presented studies estimating the EU-wide impact to range between €4.5 billion and €5 billion, with Spain potentially facing costs exceeding €500 million. Governments, including Spain, have called for an “equitable and proportional” application and a complementary impact study on the pharmaceutical sector and access to essential products.
Industry associations have proposed nine principles for RAP implementation, including excluding past investments, establishing single non-profit RAP management organizations in each state, and allocating 20% of the costs to states. They also advocate for expanding the taxpayer base to include other industries generating micropollution. In Spain, the General Directorate of Water has even considered exempting certain medications, particularly generics and critical drugs, to safeguard availability and market balance.
The ongoing discussions underscore the complex interplay between environmental protection, public health, and economic considerations as the EU navigates the implementation of this landmark directive.
Keep reading
- RAP vs. IBR: What Your New Student Loan Bill Actually Costs (daybreakwire.com)
- Rising Crime Victim Legal Costs as Prosecutor Direct Investigation Declines (archynewsy.com)
